Patents by Inventor Marcia Wolf

Marcia Wolf has filed for patents to protect the following inventions. This listing includes patent applications that are pending as well as patents that have already been granted by the United States Patent and Trademark Office (USPTO).

  • Transformed Bacteria Producing CS6 Antigens as Vaccines
    Publication number: 20080038319
    Abstract: Disclosed herein are antigens that stimulate protective antibodies against enterotoxigenic Escherichia coli. Also disclosed herein are proteins encoded by cssA and cssB genes as well as constructs containing the genes and methods of using thereof.
    Type: Application
    Filed: March 6, 2007
    Publication date: February 14, 2008
    Inventors: Marcia Wolf, Frederick Cassels, Edgar Boedeker
  • Model for testing immunogenicity of peptides
    Publication number: 20050074813
    Abstract: Assay methods for determining whether a peptide is likely to be immunogenic are based on a computer modeling of binding to a Class II MHC DR1 receptor. This is confirmed by competitive inhibition binding assays. The peptides are useful for eliciting an immune response for vaccination or the production of antibodies or T-cells.
    Type: Application
    Filed: December 17, 2003
    Publication date: April 7, 2005
    Inventors: Jeffrey Nauss, Robert Reid, Marcia Wolf, Scheherazade Sadegh-Nasseri
  • Transformed bacteria producing CS6 antigens as vaccines
    Publication number: 20050025787
    Abstract: Disclosed herein are antigens that stimulate protective antibodies against enterotoxigenic Escherichia coli. Also disclosed herein are proteins encoded by cssA and cssB genes as well as constructs containing the genes and methods of using thereof.
    Type: Application
    Filed: January 12, 2004
    Publication date: February 3, 2005
    Inventors: Marcia Wolf, Frederick Cassels, Edgar Boedeker
  • MODEL FOR TESTING IMMUNOGENCITY OF PEPTIDES
    Publication number: 20030082193
    Abstract: Assay methods for determining whether a peptide is likely to be immunogenic are based on a computer modeling of binding to a Class II MHC DR1 receptor. This is confirmed by competitive inhibition binding assays. The peptides are useful for eliciting an immune response for vaccination or the production of antibodies or T-cells.
    Type: Application
    Filed: January 26, 1998
    Publication date: May 1, 2003
    Inventors: JEFFREY L. NAUSS, ROBERT H. REID, MARCIA WOLF, Scheherazade Sadegh-Nasseri